Gotowa bibliografia na temat „Inhibiteurs de pompe à protons”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Inhibiteurs de pompe à protons”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Inhibiteurs de pompe à protons"
Faure, Sébastien. "Inhibiteurs de la pompe à protons". Actualités Pharmaceutiques 51, nr 516 (maj 2012): 55–58. http://dx.doi.org/10.1016/s0515-3700(12)71314-9.
Pełny tekst źródłaRoux, Christian. "Ostéoporose et inhibiteurs de pompe à protons". Revue du Rhumatisme Monographies 78, nr 2 (kwiecień 2011): 98–100. http://dx.doi.org/10.1016/j.monrhu.2011.01.005.
Pełny tekst źródłaMarchetti, B. "Les inhibiteurs de la pompe à protons". Acta Endoscopica 23, S3 (maj 1993): 240–45. http://dx.doi.org/10.1007/bf02969975.
Pełny tekst źródłaEsteves, Marie, Victoria Rollason i Olivier Grosgurin. "Surprescription des inhibiteurs de la pompe à protons". Revue Médicale Suisse 13, nr 579 (2017): 1782–86. http://dx.doi.org/10.53738/revmed.2017.13.579.1782.
Pełny tekst źródłaDesbuissons, Geoffroy, Gilbert Deray i Lucile Mercadal. "Inhibiteurs de la pompe à protons et rein". Néphrologie & Thérapeutique 14 (kwiecień 2018): S115—S124. http://dx.doi.org/10.1016/j.nephro.2017.06.005.
Pełny tekst źródłaPhan, C., T. Sené, M. Roumier, A. M. Piette, I. Marroun i J. E. Kahn. "Hypomagnésémie et inhibiteurs de la pompe à protons". La Revue de Médecine Interne 34 (grudzień 2013): A116. http://dx.doi.org/10.1016/j.revmed.2013.10.199.
Pełny tekst źródłaRinaldi, Y. "II.4 Inhibiteurs de la pompe à protons". Acta Endoscopica 21, S1 (styczeń 1991): 109–11. http://dx.doi.org/10.1007/bf02970832.
Pełny tekst źródłaFaure, C., C. Pelatan i J. Languepin. "Inhibiteurs de la pompe à protons en pédiatrie". Archives de Pédiatrie 6, nr 6 (czerwiec 1999): 650–56. http://dx.doi.org/10.1016/s0929-693x(99)80298-x.
Pełny tekst źródłaKherad, Omar. "Prescription inappropriée des inhibiteurs de la pompe à protons". Revue Médicale Suisse 15, nr 666 (2019): 1833. http://dx.doi.org/10.53738/revmed.2019.15.666.1833_1.
Pełny tekst źródłaFlorent, C. "Inhibiteurs de la pompe à protons: la nouvelle génération". Acta Endoscopica 32, S1 (wrzesień 2002): 445–53. http://dx.doi.org/10.1007/bf03020578.
Pełny tekst źródłaRozprawy doktorskie na temat "Inhibiteurs de pompe à protons"
Guérard, Françoise. "Une nouvelle classe d'antiulcéreux : les inhibiteurs de la pompe à protons". Paris 5, 1989. http://www.theses.fr/1989PA05P086.
Pełny tekst źródłaBarjou, Agnès. "Les inhibiteurs de la pompe à protons dans la thérapeutique de l'ulcère gastroduodénal". Bordeaux 2, 1995. http://www.theses.fr/1995BOR2P018.
Pełny tekst źródłaKRAUSER, SABINE. "L'omeprazole, un inhibiteur de la pompe a protons". Université Louis Pasteur (Strasbourg) (1971-2008), 1990. http://www.theses.fr/1990STR15073.
Pełny tekst źródłaJebbari, Mostafa. "Les inhibiteurs de la pompe à protons, l'ulcère gastroduodénal à l'heure de l'Helicobacter Pylori". Bordeaux 2, 1998. http://www.theses.fr/1998BOR2P025.
Pełny tekst źródłaMontrichard, Françoise. "Mise au point d'une méthode pour l'isolement des vacuoles et propriétés de l'ATPase pompe à protons du tonoplaste d'acer pseudoplatanus". Besançon, 1990. http://www.theses.fr/1990BESA2026.
Pełny tekst źródłaPoquet, Sandrine. "Un nouvel inhibiteur de la pompe à protons : le prantoprazole". Bordeaux 2, 1998. http://www.theses.fr/1998BOR2P047.
Pełny tekst źródłaLoui͏̈a, Franck. "Les inhibiteurs des "pompes" à protons gastriques : recherches, développements, synthèses chimiques, mécanismes d'action et relations structure-activité". Paris 5, 1994. http://www.theses.fr/1994PA05P253.
Pełny tekst źródłaEl, Chamieh Carolla. "Influence des toxines urémiques sur la morbi-mortalité cardiovasculaire des patients en Maladie Rénale Chronique dans la cohorte CKD-REIN". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASR003.
Pełny tekst źródłaChronic kidney disease (CKD) is a major public health problem, affecting more than 10% of the worldwide adult population. Patients with CKD have an increased risk of cardiovascular morbidity and mortality, highlighting the importance of identifying associated risk factors. Uremic toxins (UTs) are molecules that accumulate in patients with CKD, and which have been identified as cardiovascular risk factors specific to CKD. A narrative review, including all in vitro, in vivo, and observational studies between 2002 and 2022 evaluating the link between UTs and cardiovascular risk, was carried out at the beginning of the thesis. This allowed us to conclude that kynurenine, a protein-bound UT derived from tryptophan metabolism, has never been studied in pre-dialysis patients. Thus the second objective of the thesis evaluated the association between kynurenine and cardiovascular events. Furthermore, it is crucial to identify factors that may influence serum concentrations of UTs, for which available information is limited. Proton pump inhibitors (PPIs), commonly prescribed for patients with CKD, and certain UTs are eliminated by the organic anion transporters in the kidneys. The hypothesis of a potential interaction between PPIs and UTs has never been assessed in the literature. Hence, our last objective was to evaluate their association. The last two objectives of the thesis were conducted using data from the CKD-REIN cohort, a large prospective cohort carried out in 40 nephrology clinics in France, including patients with moderate-to-advanced CKD. We found that a doubling of serum free kynurenine levels was associated with an 19%-increased hazard of cardiovascular events (466 events, HR[95%CI]: 1.19 [1.03-1.39]), independently of glomerular filtration rate, serum free tryptophan level or other UTs, cardioprotective drugs and traditional cardiovascular risk factors. Serum free kynurenine was particularly associated with non-atheromatous cardiovascular events (HR[95%CI]: 1.31 [1.09-1.6]). However, we did not find a significant association between serum free kynurenine and all-cause mortality (311 events,HR[95%CI]: 1.18 [0.9-1.4]). In a randomly selected sub-cohort from CKD-REIN, 31% of patients had PPI prescriptions at baseline. We demonstrated that serum concentrations of free and total indoxyl sulfate, free and total p-cresyl glucuronide, and phenylacetylglutamine were significantly and independently higher in patients taking PPIs compared to those who were not. This thesis highlights the need for further research to understand the underlying mechanisms of the effect of UTs on cardiovascular health in patients with CKD and to develop new treatments and approaches to mitigate their impact on the health of these patients
Tisseyre, Mylène. "Identification d'expositions médicamenteuses in utero associées à la survenue d'infections au cours de la première année de vie". Electronic Thesis or Diss., Université Paris Cité, 2023. http://www.theses.fr/2023UNIP5294.
Pełny tekst źródłaInfant infections are a major concern in terms of global morbidity and mortality, significantly contributing to infant deaths, particularly through respiratory infections. Risk factors for severe infections in infants are multifactorial, primarily related to in utero development, prematurity, low birth weight, as well as immunological, genetic, and environmental factors. Recent data in the literature suggest that modifications in the microbiome can have immunological implications and potentially increase the risk of infection. Therefore, changes in the maternal-fetal microbiome could have consequences for the infant. Recent literature suggests associations between in utero exposure to antibiotics and an increased risk of serious infections in early childhood. These studies have been made possible, in particular, through the development of pharmacoepidemiology using medical-administrative databases, such as the National Health Data System (SNDS), allowing the creation of substantial cohorts of pregnant women. The overall objective of this thesis was to evaluate the role of medication exposures during pregnancy and the risk of serious infections in the first year of life. The research work focused on two pharmacological classes due to their frequent use during pregnancy and their impact on the maternal-fetal microbiome: antibiotics and proton pump inhibitors. Firstly, a national cohort study, including 2.8 million full-term infants, evaluated the association between in utero exposure to systemic antibiotics and the occurrence of serious infections in full-term infants during their first year of life. The results revealed a moderate increase in the incidence of serious infections in infants exposed in utero to systemic antibiotics. Associations were similar regardless of the trimester of exposure, antibiotic class, and infection sites. However, infants exposed to broad-spectrum antibiotics or three or more antibiotic courses appeared to have a slightly increased risk, supporting a potential causal relationship. Secondly, another study, stratified by the use of proton pump inhibitors during the first three months of life and including 2.1 million full-term infants, explored the impact of prenatal exposure to proton pump inhibitors on the occurrence of serious infections during their first year of life. The results ruled out a significant association between the use of proton pump inhibitors during pregnancy and the occurrence of serious infections in infants. Nevertheless, even after adjusting for several confounding factors, this study did not exclude a limited residual risk, restricted only to infants with proton pump inhibitors use in early life. In conclusion, this thesis confirmed existing data on an association between exposure to antibiotics during pregnancy, which strongly affects the microbiome, and the occurrence of serious infections in infants. The results are more reassuring concerning proton pump inhibitors; although a low risk cannot be completely ruled out. These findings need confirmation through further studies. They have contributed to expanding the knowledge regarding the safety of medication use during pregnancy
Rodier, Jean-Gilles. "Inhibiteur de la pompe à protons contre Nissen par laparoscopie : une évaluation médico-économique du traitement du refluxgastro-oesophagien de l'adulte selon un modèle de Markov". Montpellier 1, 1999. http://www.theses.fr/1999MON11082.
Pełny tekst źródłaCzęści książek na temat "Inhibiteurs de pompe à protons"
"Inhibiteurs de la pompe à protons (IPP)". W Méga Guide STAGES IFSI, 914. Elsevier, 2015. http://dx.doi.org/10.1016/b978-2-294-74529-4.00286-x.
Pełny tekst źródłaAlexandre, J., A. Balian, L. Bensoussan, A. Chaïb, G. Gridel, K. Kinugawa, F. Lamazou i in. "Inhibiteurs de la pompe à protons (IPP)". W Le tout en un révisions IFSI, 836. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70633-2.50279-1.
Pełny tekst źródła